Research_医药人-Daniel:Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
ADC TROP-2跌去10个点
考拉荷:$前沿生物-U(SH688221)$ $吉利德科学(GILD)$ 吉利德跳空高开高走,最新财报显示新冠住院药物瑞德西韦收入大超预期。吉利德Q3营收70.42亿美元,超出市场预期61.2亿美元;新冠药物销售额大超预期,再次上调全年业绩指引,第三季度的销售额为9.25亿美元,几乎是市场预期的三倍。吉利德首席执行官Daniel O